Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Sep 19 2023

Full Issue

Drugmaker Mallinckrodt May Be Considering Exiting Opioid Business

The pharmaceutical maker is one of the largest U.S. producers of prescription opioids, the Wall Street Journal reminds us, and it's in talks with its investors about selling a portion or all of its business units. Meanwhile, in San Francisco, fentanyl overdose deaths are rising again.

The Wall Street Journal: Bankrupt Drugmaker Mallinckrodt Considers Sale Of Opioid Business 

Pharmaceutical manufacturer Mallinckrodt, one of America’s largest producers of prescription opioids, is in talks with its major investors about selling some or all of the company’s business units, potentially leading to its exit from the opioid business, according to people familiar with the discussions. (Saeedy, 9/18)

More on the opioid crisis —

San Francisco Chronicle: San Francisco Drug Overdose Death Numbers Are Rising Again

The numbers underscore how San Francisco officials continue to struggle to address the devastation of fentanyl on the city’s streets — a crisis that Health Director Dr. Grant Colfax called “distressing.” The last figures indicate people are dying from fentanyl overdoses at a rate of nearly three people a day. Colfax and and other health leaders on Monday announced a renewed push to urge people struggling with addiction to seek treatment. (Ho and Leonard, 9/18)

The New York Times: Fentanyl Found Near Nap Mats At Day Care Where Boy Died, Police Say

A kilogram of fentanyl was found near mats that children used for napping at a Bronx day care site where one toddler died and three other children were hospitalized last week, the police said on Monday night. Chief Joseph Kenny, the Police Department’s chief of detectives, explained just how close to the children the potent narcotic was: “It was laid underneath a mat where the children had been sleeping earlier,” he said at a news conference, where he joined Mayor Eric Adams and other city officials. (Kilgannon and Shanahan, 9/18)

The Washington Post: Sober Homes Promised Help And Shelter. Some Delivered Fraud, Officials Say. 

In August, the New Mexico attorney general unveiled a campaign warning unsheltered people from “being lured” into traveling across state lines “to illegitimate recovery facilities.” The Blackfeet Nation in Montana in July declared a state of emergency aimed at helping displaced members, while one of the state’s senators, Jon Tester (D), demanded an investigation from the federal agency that oversees Medicaid services. (Ovalle, 9/18)

The Washington Post: How One Company Profited While Delaying Narcan’s Drugstore Debut

Five years after public health officials first asked for it, Narcan finally hit store shelves this month — a potentially pivotal moment in the fight to counter the country’s stubbornly high death toll from heroin, fentanyl and pain pills. Now, anyone can buy the opioid overdose reversal drug without a prescription. But it almost didn’t happen. Narcan’s maker, Emergent BioSolutions, for years refused to allow its blockbuster drug to be sold over the counter (known as OTC), frustrating health experts and workers on the epidemic’s front lines who saw making Narcan and other naloxone-based medicines easier to buy as a way to save lives. (Frankel, 9/18)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF